What LillyDirect is and when it wins
LillyDirect is Eli Lilly’s direct-to-patient Zepbound self-pay program. It launched in August 2024 for 2.5 mg and 5 mg vials at $399 and $549, and repriced to $349/$499 in early 2026 as competitive pressure from compounded tirzepatide and NovoCare’s Wegovy vial program mounted. Lilly positions it as the self-pay option for patients whose insurance doesn’t cover anti-obesity medications.
LillyDirect wins clearly in exactly one scenario: your plan doesn’t cover AOMs, and you want branded product with FDA-validated manufacturing. It loses to insurance-with-savings-card when you have coverage ($25–$100 copays), and it loses to the cheapest compounded telehealth programs on pure monthly price (compounded can hit $199–$299 on 503A programs that still exist in 2026).
The 2026 price list
- 2.5 mg (starter dose): $349/mo. Typically 4 weeks of once-weekly injections.
- 5 mg: $499/mo.
- 7.5 mg: $499/mo.
- 10 mg: $499/mo.
- 12.5 mg: $499/mo.
- 15 mg (max therapeutic): $499/mo.
Month 1–4 annual math (standard titration): $349 × 1 + $499 × 11 = $5,838 year one. Post-titration annual (maintenance at any therapeutic dose): $499 × 12 = $5,988.
Five-year budget scenarios
Most obesity-medicine physicians now treat GLP-1 as indefinite maintenance therapy. A five-year LillyDirect cost at the maintenance dose is $499 × 60 = $29,940, or $5,988/year. Running at a lower maintenance dose is not currently a LillyDirect pricing lever — the $499 price applies to all therapeutic doses uniformly. That’s different from the pen channel, where some plans will cover a lower dose more cheaply than a higher one.
LillyDirect vs NovoCare (Wegovy)
NovoCare sells Wegovy vials at $499/mo for both the 1.7 mg and the top 2.4 mg doses. Same price band as LillyDirect at therapeutic doses, with a lower starter-dose price on LillyDirect’s side ($349 for 2.5 mg Zepbound vs $499 for 1.7 mg Wegovy). If you’re choosing between AOMs and both are out-of-pocket, the drug choice should come down to efficacy (tirzepatide beat semaglutide in SURMOUNT-5), side-effect profile, and indication fit (SELECT CV → Wegovy; SURMOUNT-OSA → Zepbound).
LillyDirect vs pharmacy list price
Zepbound list price at retail pharmacies in 2026 is approximately $1,060/mo. LillyDirect at $499 saves you $561/mo or $6,732/year on maintenance. Over five years that’s $33,660 in saved cash. The tradeoff: you inject from a vial rather than from a pen autoinjector.
Practical tips
- Stack with HSA/FSA for a 22–32% effective discount.
- Order the next month’s supply when you’re at 10–14 days of inventory left.
- If you’re on a therapeutic dose, don’t titrate down to save money — the price is flat at $499.
- If your insurance later covers Zepbound, cancel LillyDirect auto-refill and move to the savings-card path.
- Keep vials refrigerated; unrefrigerated exposure shortens shelf life.